These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 15111244)

  • 21. The role of the adenosinergic system in lung fibrosis.
    Della Latta V; Cabiati M; Rocchiccioli S; Del Ry S; Morales MA
    Pharmacol Res; 2013 Oct; 76():182-9. PubMed ID: 23994158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease.
    Carta AR; Kachroo A; Schintu N; Xu K; Schwarzschild MA; Wardas J; Morelli M
    J Neurochem; 2009 Dec; 111(6):1478-89. PubMed ID: 19817968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of SCH 58261, an adenosine A(2A) receptor antagonist, on quinpirole-induced turning in 6-hydroxydopamine-lesioned rats. Lack of tolerance after chronic caffeine intake.
    Popoli P; Reggio R; Pèzzola A
    Neuropsychopharmacology; 2000 May; 22(5):522-9. PubMed ID: 10731627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease.
    Ochi M; Shiozaki S; Kase H
    Neuroscience; 2004; 127(1):223-31. PubMed ID: 15219684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An overview of adenosine A2A receptor antagonists in Parkinson's disease.
    Jenner P
    Int Rev Neurobiol; 2014; 119():71-86. PubMed ID: 25175961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
    Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel adenosine A(1) and A(2A) receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: comparison with existing anti-Parkinson's disease drugs.
    Mihara T; Iwashita A; Matsuoka N
    Behav Brain Res; 2008 Dec; 194(2):152-61. PubMed ID: 18657577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
    Rose S; Jackson MJ; Smith LA; Stockwell K; Johnson L; Carminati P; Jenner P
    Eur J Pharmacol; 2006 Sep; 546(1-3):82-7. PubMed ID: 16925991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of tolerance to motor stimulant effects of a selective adenosine A(2A) receptor antagonist.
    Halldner L; Lozza G; Lindström K; Fredholm BB
    Eur J Pharmacol; 2000 Oct; 406(3):345-54. PubMed ID: 11040341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PBF509, an Adenosine A
    Núñez F; Taura J; Camacho J; López-Cano M; Fernández-Dueñas V; Castro N; Castro J; Ciruela F
    Front Pharmacol; 2018; 9():1200. PubMed ID: 30405415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adenosine A(2A) receptors in Parkinson's disease treatment.
    Cieślak M; Komoszyński M; Wojtczak A
    Purinergic Signal; 2008 Dec; 4(4):305-12. PubMed ID: 18438720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
    Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
    Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
    Morin N; Grégoire L; Morissette M; Desrayaud S; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2013 Mar; 66():355-64. PubMed ID: 22884464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can adenosine A
    Kanda T; Jenner P
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S21-S27. PubMed ID: 33349576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists.
    Petzer JP; Steyn S; Castagnoli KP; Chen JF; Schwarzschild MA; Van der Schyf CJ; Castagnoli N
    Bioorg Med Chem; 2003 Apr; 11(7):1299-310. PubMed ID: 12628657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys.
    Grondin R; Bédard PJ; Hadj Tahar A; Grégoire L; Mori A; Kase H
    Neurology; 1999 May; 52(8):1673-7. PubMed ID: 10331698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SCH 58261, a selective adenosine A2A receptor antagonist, decreases the haloperidol-enhanced proenkephalin mRNA expression in the rat striatum.
    Wardas J; Pietraszek M; Dziedzicka-Wasylewska M
    Brain Res; 2003 Jul; 977(2):270-7. PubMed ID: 12834887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets.
    Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
    Eur J Pharmacol; 2015 Nov; 766():25-30. PubMed ID: 26415982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adenosine A2A receptors modify motor function in MPTP-treated common marmosets.
    Kanda T; Tashiro T; Kuwana Y; Jenner P
    Neuroreport; 1998 Aug; 9(12):2857-60. PubMed ID: 9760134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders.
    Hodgson RA; Bedard PJ; Varty GB; Kazdoba TM; Di Paolo T; Grzelak ME; Pond AJ; Hadjtahar A; Belanger N; Gregoire L; Dare A; Neustadt BR; Stamford AW; Hunter JC
    Exp Neurol; 2010 Oct; 225(2):384-90. PubMed ID: 20655910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.